• AngioDynamics (Queensbury, New York) a company that makes devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, reported that the U.S. Bankruptcy Court for the District of Massachusetts, Western Division, has granted an order approving AngioDynamics' purchase of certain U.S. assets of Diomed Holdings (Andover, Massaschusetts) and its subsidiary, Diomed (Andover). AngioDynamics has agreed to pay $8 million in cash for the assets and U.S. $3 million in cash for certain UK assets of Diomed Ltd. The final purchase price will be subject to adjustment for changes in working capital at the closing date, the company noted. AngioDynamics said it expected that it would simultaneously close the purchase of both the U.S. and UK assets in June. On April 10 AngioDynamics said it had entered into asset purchase agreements with Diomed Holdings, Diomed and Diomed Ltd. for the acquisition of certain assets of Diomed's business in the U.S. and UK. The agreement was subject to an auction process administered by the bankruptcy court as a result of Diomed's Chapter 11 bankruptcy proceedings. Diomed's U.S. and UK businesses are engaged in the sale of systems for the endovenous laser treatment of varicose veins.

• Applera (Norwalk, Connecticut) reported approval of separating the Celera Group (Nashville, Tennessee) from Applera's remaining businesses, accomplished by the redemption of outstanding shares of Applera-Celera Group tracking stock, with Celera becoming an independent public company. Berkeley HeartLab (Burlingame, California), a Celera subsidiary, offers services to predict cardiovascular disease risk and optimize patient management.

• Boston Scientific (Natick, Massachusetts) reported completing its previously disclosed $17.6 million acquisition of CryoCor (San Diego), a company developing treatment of cardiac arrhythmias. All remaining outstanding CryoCor shareholders are entitled to receive $1.35 a share in cash. CryoCor is now an indirect, wholly-owned subsidiary of Boston Scientific. The acquisition follows on the heels of an agreement between the two companies, in place since June 2007, to pursue therapeutic solutions for atrial fibrillation.

• MedCath (Charlotte, North Carolina), its physician partners, and Good Samaritan Hospital (Dayton, Ohio), reported completing the previously disclosed sale of Dayton Heart Hospital to Good Samaritan Hospital. Good Samaritan purchased substantially all of Dayton Heart's assets for $55 million. Dayton Heart is a 47-bed hospital providing cardiovascular care to the Dayton community.

• Mindray Medical International (Shenzhen, China) said it has completed its acquisition of Datascope's (Montvale, New Jersey) patient monitoring device business, a deal first disclosed in March. The deal has a pre-tax value to Datascope of $240 million. Mindray paid $209 million in cash and Datascope retained about $31 million in patient monitoring accounts receivable. The combined business benefits from Mindray's engineering and manufacturing platforms, Datascope's brands, products and services and direct sales and service capabilities in the U.S. and Western Europe, the company said. Mindray said it expects to achieve more than $30 million in run-rate synergies from the acquisition in 2011. Mindray offers products across three primary business segments: patient monitoring and life support products, in vitro diagnostic products and medical imaging.

• Royal Philips Electronics (Amsterdam, the Netherlands) said that it agreed to acquire Dixtal Biomédica e Tecnologia (S o Paulo, Brazil). Terms were not disclosed. Dixtal manufactures in-hospital patient monitoring, anesthesia and ventilation equipment, and ECGs as well as other sensors for vital sign measurements. It will become part of the Patient Monitoring business within Philips' Healthcare. Philips said it expects Dixtal's financial results consolidated in that business as of 3Q08. Dixtal employs about 300, mainly in Brazil, of which 60 work in R&D.

• Spectranetics (Colorado Springs) reported that it closed its bid to acquire the endovascular business of Kensey Nash (Exton, Pennsylvania) and has begun selling the acquired products. The deal consists of a $10 million initial payment, $8 million in future product development milestone payments, and a $6 million milestone associated with cumulative sales.The actual closing date was May 30. The endovascular unit, which made up about 11% of Kensey's third-quarter sales, includes the ThromCat, QuickCat and SafeCross products, all of which are used to treat blood clots and blockages in arteries.

• Volcano (Rancho Cordova, California), a provider of IVUS, FM and OCT products for enhancing the diagnosis and treatment of coronary and peripheral vascular disease, has acquired Novelis (Methuen, Massachusetts), a private developer of ultrasonic visualization and therapy technology for minimally invasive diagnostic and therapeutic devices. Volcano paid about $12 million in cash at closing. and may make an additional payment of $3 million, based on a specific regulatory milestone. Volcano said that Novelis' IVUS technology platform will enhance its position as an imaging technology leader.